The marijuana industry is spending millions on a lobbying blitz to convince President Donald Trump to reclassify marijuana as a less harmful substance. While the push is being marketed as a step toward modernization, critics warn that ignoring the real marijuana risks could have lasting consequences for public health and safety.
At a recent $1 million-a-plate fundraiser, Trump told attendees he was considering moving marijuana from Schedule I — the most restrictive classification under the Controlled Substances Act — to Schedule III, which includes substances like ketamine and codeine. This shift would open the door to easier and wider marijuana use, while giving the already booming cannabis industry greater access to financing. Among those present was Kim Rivers, CEO of Trulieve, one of the largest marijuana companies in the country.
Trump has previously signaled openness to marijuana reform, even supporting Florida’s legalization referendum last fall. But opponents argue that such a move ignores the mounting evidence of marijuana risks.
Critics point to data showing that marijuana is far from harmless. The Soros-funded Drug Policy Alliance has spent millions advancing legalization efforts, yet states that embraced legalization have seen troubling trends. Youth cannabis use has surged by 245% over the past two decades, and modern marijuana strains are up to three times stronger than in the past, amplifying the marijuana risk for addiction and mental health issues.
Perhaps most concerning is the connection between marijuana legalization and the opioid crisis. Research from the National Bureau of Economic Research found that legalization correlates with higher opioid death rates. Trump himself warned in 2017 that “drugs are becoming cheaper than candy bars,” underscoring the need to address all forms of substance abuse, including the hidden marijuana risks.
Supporters of reclassification argue it would align federal policy with public opinion, which leans toward legalization. However, critics say popularity should not override science and public safety concerns. Allowing broader marijuana commercialization could intensify urban quality-of-life problems, such as the pervasive “skunk” smell in cities like Washington, D.C., a reminder of the social costs tied to marijuana risks.
The White House has stated that “all policy and legal requirements and implications are being considered.” For those concerned about marijuana risks, the path forward is clear: keep marijuana in its current Schedule I classification to prevent further harm to communities.
Ultimately, the decision will test whether President Trump prioritizes political popularity or long-term public health. On an issue where the stakes are high, acknowledging the reality of marijuana risks should guide the choice.